Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class i chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma

Cancer

Volumn 119, Issue 1, 2013, Pages 233-244

  Chung, Hye Won ^a   Jang, Sunphil ^a   Lim, Jong Baeck ^a  

^a Yonsei University   (South Korea)

Author keywords

cytokines; diagnostic accuracy; pancreatic ductal adenocarcinoma; relationship; soluble major histocompatibility complex class I chain related molecule A

Indexed keywords

CA 19-9 ANTIGEN; CD40 LIGAND; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; CHEMOLUMINESCENCE; CHRONIC PANCREATITIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

CARCINOMA, PANCREATIC DUCTAL; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 84872768510     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27669     Document Type: Article

References (24)

1. Chappell DB, Restifo NP,. T cell-tumour cell: a fatal interaction? Cancer Immunol Immunother. 1998; 47: 65-71.
2. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU,. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996; 42: 1-8.
3. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999; 155: 537-547.
4. Salazar-Onfray F, Lõpez MN, Mendoza-Naranjo A,. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007; 18: 171-182.
5. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001; 97: 3146-3151.
6. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science. 1999; 285: 727-729.
7. Groh V, Wu J, Yee C, Spies T,. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419: 734-738.
8. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR,. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004; 114: 560-568.
9. Farrow B, Albo D, Berger DH,. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008; 149: 319-328.
10. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R,. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004; 101: 2727-2736.
11. Poch B, Lotspeich E, Ramadani M, Gansauge S, Beger HG, Gansauge F,. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg. 2007; 392: 353-358.
12. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M,. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 13: 565-569.
13. Märten A, von Lilienfeld-Toal M, Büchler MW, Schmidt J,. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer. 2006; 119: 2359-2365.
14. Chung HW, Lim JB,. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. Cancer Sci. 2011; 102: 1673-1679.
15. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R,. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010; 21: 27-39.
16. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE,. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev. 2007; 18: 159-170.
17. Lange F, Rateitschak K, Fitzner B, Pöhland R, Wolkenhauer O, Jaster R,. Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach. Mol Cancer. 2011; 10: 13-25.
18. Schmiegel W, Roeder C, Schmielau J, Rodeck U, Kalthoff H,. Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A. 1993; 90: 863-867.
19. Datta D, Flaxenburg JA, Laxmanan S, et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006; 66: 9509-9518.
20. Karademir S, Sökmen S, Terzi C, et al. Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000; 7: 489-495.
21. Melter M, Reinders ME, Sho M, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000; 96: 3801-3808.
22. Roselli M, Mineo TC, Basili S, et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res. 2004; 10: 610-614.
23. Xie K,. Survey: interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12: 375-391.
24. Korc M,. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer. 2003; 2: 8-15.